Charles Schwab Investment Management Inc Palatin Technologies Inc Transaction History

Charles Schwab Investment Management Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.27 - $0.5 $34,905 - $64,639	129,279 New	129,279 $37,000
Q1 2022 May 13, 2022	SELL	$0.37 - $0.54 $21,053 - $30,726	-56,900 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$0.41 - $0.73 $198,928 - $354,190	-485,192 Reduced 89.5%	56,900 $30,000
Q4 2019 Feb 07, 2020	BUY	$0.75 - $0.89 $53,011 - $62,906	70,682 Added 14.99%	542,092 $425,000
Q4 2018 Feb 14, 2019	BUY	$0.63 - $1.0 $31,065 - $49,310	49,310 Added 11.68%	471,410 $334,000
Q3 2018 Nov 13, 2018	BUY	$0.88 - $1.1 $50,072 - $62,590	56,900 Added 15.58%	422,100 $422,000
Q2 2018 Aug 08, 2018	BUY	$0.91 - $1.45 $332,332 - $529,540	365,200 New	365,200 $355,000

2.94K

Ticker PTN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 9,290,480
Market Cap $9.01M
Description
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing o...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.